4th Quarter - Report

THE MCMANUS GROUP for GENENTECH

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 1548, "Pathway for Biosimilars Act." Follow-on biologics provisions in H.R. 3962, "Affordable Health Care for America Act," and H.R. 3590, "Patient Protection and Affordable Care Act."

Foreign entity interest: 100% ownership by Roche Holding, Ltd., 4070 Basel, Switzerland

LobbyistCovered position, as disclosed
JOHN MCMANUS —
NICK SHIPLEY Legislative Director, Rep. Jay Inslee

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3962 (111th), H.R. 1548 (111th), H.R. 3590 (111th)

Medicare/Medicaid MMM

Opposition to Medicare rebates in H.R. 3962, "Affordable Health Care for America Act," and H.R. 3590, "Patient Protection and Affordable Care Act." Independent Payment Advisory Board provisions in H.R. 3590, "Patient Protection and Affordable Care Act." Coding and payment for follow-on biologics in H.R. 3962, "Affordable Health Care for America Act," and H.R. 3590, "Patient Protection and Affordable Care Act."

Foreign entity interest: 100% ownership by Roche Holding, Ltd., 4070 Basel, Switzerland

LobbyistCovered position, as disclosed
JOHN MCMANUS —
NICK SHIPLEY Legislative Director, Rep. Jay Inslee

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3590 (111th), H.R. 3962 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.